Cardiovascular and bleeding risks of inactive cancer in patients with acute myocardial infarction who received primary percutaneous coronary intervention using drug-eluting stent and dual/triple antithrombotic therapy.

Publication Year: 2022

DOI:
10.21037/cdt-22-306

PMCID:
PMC9808111

PMID:
36605075

Journal Information

Full Title: Cardiovasc Diagn Ther

Abbreviation: Cardiovasc Diagn Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Cardiac & Cardiovascular Systems

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of Interests: All authors have completed the ICMJE uniform disclosure form (available at https://cdt.amegroups.com/article/view/10.21037/cdt-22-306/coif). YK serves as an unpaid editorial board member of Cardiovascular Diagnosis and Therapy from September 2021 to August 2023, and has received research support from Nipro and Abbott, and honoraria from Nipro, Abbott, Kowa, Amgen, Sanofi, Astellas, Takeda and Daiichi-Sankyo. The other authors have no conflicts of interest to declare."

Evidence found in paper:

"Funding: None."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025